Evidence map›Paper›PMID 26201621›Full record

ArticleHepatology international2013

Adenoviral gene therapy in hepatocellular carcinoma: a review.

Iván Lyra-González, Laura Esther Flores-Fong, Ignacio González-García, David Medina-Preciado, Juan Armendáriz-Borunda

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Iván Lyra-GonzálezDepartment of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, Sierra Mojada #950, 44281, Guadalajara, JAL, Mexico.
Laura Esther Flores-FongDepartment of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, Sierra Mojada #950, 44281, Guadalajara, JAL, Mexico.
Ignacio González-GarcíaO.P.D. Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, JAL, Mexico.
David Medina-PreciadoO.P.D. Hospital Civil de Guadalajara, Juan I. Menchaca, Guadalajara, JAL, Mexico.
Juan Armendáriz-BorundaDepartment of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, Sierra Mojada #950, 44281, Guadalajara, JAL, Mexico. armdbo@gmail.com.
Hospital Civil de Guadalajara · MXUniversidad de Guadalajara · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma is the third leading cause of cancer death. Single or multiple mutations in genes related to growth control, apoptosis, invasion and metastasis have been determined; so a better understanding of the molecular genetic basis of malignant transformation, tumor progression and host interaction has led to significant progress in the development of new therapeutic agents. The ability of adenovirus vectors to deliver and express genes at high yields in HCC treatment has been demonstrated and well documented over the last few years.

objectiveTo overview and provide an update of what has been accomplished in the field of adenoviral gene therapy and its application in hepatocellular carcinoma treatment.

methodsOriginal articles were searched using Pubmed and other medical databases to get the most representative and actual information to establish the current state of the investigation of Ad vectors in HCC.

resultsGood results have been accomplished in preclinical models using new Ad vectors and especially AAV vectors, it is important to motivate further clinical trials to corroborate all the experience obtained.

conclusionsAd and AAV must be considered as an opportunity to improve the quality of life and survival of HCC patients.

Indexed as

Adenoviral gene therapyCancer treatmentGene therapyHCCHepatocellular carcinomaLiver cancer

Identifiers

PMID26201621
OpenAlexW1987919159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.